The national vaccination campaign for pediatric ages in Nicaragua began on October 25th and extends to the population segment between two and 17 years of age.
Cuba had already sent a first shipment of 1,200,000 doses of the vaccines Soberana 02 and Abdala, the latter belonging to the Center for Genetic Engineering and Biotechnology.
Both vaccines were approved for emergency use by the Sanitary Regulation authority of the Ministry of Health of Nicaragua.
Other countries such as Iran, Venezuela and Vietnam have made use of vaccines created by Cuban scientific institutions.
Deliveries from the Cuban pharmaceutical industry will conclude in December with 1.1 million doses of Soberana Plus and 1.3 million of Abdala.
The agreement with Cuba provides for the delivery to Nicaragua of a total of seven million doses of Cuban vaccines during the last quarter of the year.
pgh/llp/mem/cdg